Please login to the form below

Not currently logged in
Email:
Password:

Bayer president Andreas Fibig set to depart

Will become CEO of International Flavors & Fragrances

Andreas-Fibig-BayerBayer Healthcare's president Andrea Fibig is to leave to become CEO of International Flavors & Fragrances (IFF).

Fibig has served as president of Bayer Healthcare since 2008, during which time he has been head of the company's pharmaceuticals division and a member of the executive committee.

The appointment at IFF marks a departure for Fibig who has been in the pharma industry since the early 1980s, serving at Schering and Boehringer Ingelheim in his early years.

In 2000 he went on to serve as present of Pharmacia & Upjohn's operations in Germany before joining Pfizer as president for its operations in Latin America, Africa and the Middle East and then serving as senior VP and general manager for Pfizer in the US.

This experience in the US will benefit Fibig in his first CEO position as he takes over from Doug Tough at New York-based IFF, which develops and creates flavors and fragrances for consumer products.

Tough commented that Fibig “brings the right combination of experience and skills”.

“He has led businesses with an international footprint similar to ours, has firsthand experience in key emerging markets where we see further opportunity, and understands the critical importance of science-based research in driving innovation and competitiveness,” he added.

Tough also remarked that Fibig knows IFF well due to serving as a board member since 2011.

As for who will replace Fibig at Bayer, the company stated a successor will be announced “in a few days”.

29th May 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics